Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 7/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | ATP4A | P20648 | 8/20 | 0.39 |
| ▸ | ATP4B | P51164 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5424346 | 0.91 | L3MBTL1 (0.46) | L3MBTL1POLBKMT2AMEN1RAB9A | |
| SCHEMBL4655753 | 0.89 | POLB (0.44) | L3MBTL1POLBKMT2AMEN1RAB9A | |
| SCHEMBL14409884 | 0.85 | MEN1 (0.39) | L3MBTL1POLBKMT2AMEN1RAB9A | |
| SCHEMBL4655525 | 0.85 | POLB (0.41) | L3MBTL1POLBKMT2AMEN1RAB9A | |
| SCHEMBL4656737 | 0.83 | ATP4A (0.50) | L3MBTL1POLBKMT2AMEN1RAB9A | |
| SCHEMBL5424455 | 0.81 | KMT2A (0.48) | KMT2AMEN1RAB9ANPC1ATP4A | |
| SCHEMBL4657867 | 0.81 | NPC1 (0.42) | L3MBTL1POLBKMT2AMEN1RAB9A | |
| SCHEMBL5428280 | 0.81 | NPC1 (0.42) | KMT2AMEN1RAB9ANPC1ATP4A | |
| SCHEMBL4655532 | 0.81 | NPC1 (0.42) | KMT2AMEN1RAB9ANPC1ATP4A | |
| SCHEMBL4655600 | 0.79 | KMT2A (0.48) | KMT2AMEN1RAB9ANPC1ATP4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460800-A1 | Substituted aminothiazole derivatives with anti-HCV activity | Achillion Pharmaceuticals, Inc. (US) | 2012-06-06 | — | — | EP | claimed |
| EP-1996565-A2 | SUBSTITUTED AMINOTHIAZOLE DERIVATIVES WITH ANTI-HCV ACTIVITY | Achillion Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | claimed |
| WO-2007103550-A2 | SUBSTITUTED AMINOTHIAZOLE DERIVATIVES WITH ANTI-HCV ACTIVITY | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | claimed |
| EP-2460800-A1 | Substituted aminothiazole derivatives with anti-HCV activity | Achillion Pharmaceuticals, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | EIF2AK2, BCAT1, IL4I1 | L3MBTL1 3225/4885POLB 477/4885KMT2A 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.